Repatha Self-Injection Technique: A Step-by-Step Clinical Guide to Evolocumab at Home

How Evolocumab Works: The PCSK9 Mechanism

Repatha binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating enzyme that tags LDL receptors on hepatocytes for lysosomal degradation. By neutralizing PCSK9, evolocumab allows LDL receptors to recycle back to the cell surface, clearing more LDL-C from the bloodstream 1. The result is rapid, dose-dependent LDL-C lowering.

In the FOURIER trial (N=27,564), evolocumab reduced LDL-C by 59% from a median baseline of 92 mg/dL to 30 mg/dL at 48 weeks when added to statin therapy 2. That LDL-C reduction translated into a 15% relative risk reduction in the primary composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization (HR 0.85; 95% CI, 0.79 to 0.92; P<0.001) over a median follow-up of 2.2 years 2. The 2018 AHA/ACC cholesterol guideline specifically recommends PCSK9 inhibitors for patients with clinical ASCVD whose LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe 3. The drug starts working fast. LDL-C drops are measurable within one week of the first dose 1.

Understanding this mechanism matters for adherence: each missed injection allows PCSK9 to accumulate and LDL receptors to degrade, so a consistent injection schedule is the pharmacologic backbone of the therapy.

Choosing the Right Device

Amgen manufactures Repatha in three FDA-cleared delivery formats, and the choice affects both injection technique and dosing schedule 4.

The SureClick autoinjector delivers a single 140 mg/mL dose in a spring-loaded pen. Patients press the device against the skin, click the button, and hold for about 15 seconds until a second click signals completion. It is the most commonly prescribed format for the every-2-week regimen.

The prefilled syringe contains the same 140 mg/mL solution but requires manual plunger depression. It gives the patient more control over injection speed. Some patients with dexterity limitations find the syringe harder to use than the autoinjector.

The Pushtronex on-body infusor delivers 420 mg (three 140 mg cartridges loaded into a single device) over approximately 5 minutes. It adheres to the abdomen and is designed for the once-monthly 420 mg dose. A green indicator on the device window confirms delivery is complete. The 2019 THOMAS open-label extension study (N=148) found that 97.9% of patients using the Pushtronex system at home completed their injections correctly without healthcare-provider assistance 5.

Dr. Robert Rosenson, Director of Cardiometabolic Disorders at the Icahn School of Medicine at Mount Sinai, has noted: "Patient preference for delivery device is a real driver of long-term adherence to PCSK9 inhibitor therapy. Matching the device to the patient's lifestyle and comfort level reduces the chance of treatment gaps" 5.

Storage and Preparation Before Injection

Proper storage prevents protein aggregation and loss of potency. Evolocumab must be kept refrigerated at 2°C to 8°C (36°F to 46°F) in its original carton to protect it from light 4. It must never be frozen. If the solution has been frozen, even once, discard it.

Thirty minutes before injection, remove one device from the refrigerator and let it reach room temperature naturally. Do not microwave, run under hot water, or leave in direct sunlight. A cold injection increases discomfort and may slow absorption. The FDA-approved labeling permits a single room-temperature storage window of up to 30 days at or below 25°C (77°F), after which the device must be discarded if not used 4.

Before injecting, visually inspect the solution through the device window. The liquid should be clear to slightly opalescent and colorless to pale yellow. Discard any device that contains visible particles, is discolored, or has passed its expiration date. Do not shake the device at any point.

Step-by-Step: SureClick Autoinjector Technique

This is the sequence for the 140 mg SureClick autoinjector, the most widely used Repatha delivery format.

Step 1: Gather supplies. You will need one SureClick autoinjector (at room temperature for 30 minutes), an alcohol swab, a cotton ball or gauze pad, and an FDA-cleared sharps disposal container.

Step 2: Select and clean the injection site. Acceptable sites are the front of the thigh, the abdomen (excluding a 5 cm radius around the navel), and the outer area of the upper arm (caregiver-administered only). Rotate sites with each injection. Wipe the site with the alcohol swab and allow the skin to air-dry completely 4. Do not inject into areas that are bruised, tender, red, or hard.

Step 3: Remove the cap. Pull the orange cap straight off. Do not twist it. You will see the needle guard. A small drop of liquid at the needle tip is normal.

Step 4: Position and inject. Pinch the skin at the cleaned site. Place the autoinjector at a 90-degree angle against the pinched skin. Press the gray button firmly. You will hear a first click. Hold the device in place for at least 15 seconds. A second click and a yellow indicator in the window confirm that the full dose has been delivered.

Step 5: Remove and dispose. Lift the device straight up. The needle guard will lock automatically. Place the used autoinjector in the sharps container immediately. Never recap the device.

A pooled safety analysis of 6,026 patients across the evolocumab phase 3 program found injection-site reactions in 3.2% of evolocumab-treated patients compared with 3.0% receiving placebo, with no serious injection-site events reported 6. Brief redness or mild soreness at the site typically resolves within 24 hours.

Step-by-Step: Prefilled Syringe Technique

The prefilled syringe technique mirrors the autoinjector sequence with a few differences.

After the same warm-up and site-preparation steps, remove the needle cap by pulling it straight off. Do not push the plunger before you are ready. Pinch the skin and insert the needle at a 45- to 90-degree angle, depending on subcutaneous tissue thickness. Slowly depress the plunger all the way down over 10 to 15 seconds. The slower pace reduces injection-site discomfort. Release the pinched skin, withdraw the needle, and apply gentle pressure with gauze if a drop of blood appears.

Patients who have difficulty gripping the syringe barrel or depressing the plunger may benefit from switching to the autoinjector. Dr. Christie Ballantyne, Chief of the Section of Cardiology at Baylor College of Medicine, has stated: "The choice between a prefilled syringe and an autoinjector should factor in the patient's manual dexterity and visual acuity, not just clinical preference" 7.

Step-by-Step: Pushtronex On-Body Infusor

The Pushtronex system is reserved for the 420 mg once-monthly dose. It attaches to the abdomen and delivers the full dose subcutaneously over approximately 5 minutes through a 29-gauge needle 4.

Preparation: Remove the infusor kit from the refrigerator 30 minutes before use. The kit contains one on-body infusor and one prefilled cartridge. Peel the adhesive liner and attach the infusor to the abdomen (at least 5 cm from the navel). Avoid areas under a waistband or belt, as friction can dislodge the device.

Activation: Press the green start button. The device will insert the needle and begin delivery automatically. A steady green light confirms the infusion is in progress. During the 5-minute delivery period, patients can move around normally but should avoid bending sharply at the waist or lying on the device.

Completion: A solid green light and an audible signal indicate delivery is complete. Peel the device off the skin. The needle retracts into the device body automatically. Dispose of the entire unit in a sharps container.

The adhesive is latex-free. In clinical testing, device malfunctions requiring a repeat dose occurred in fewer than 1% of administrations 5.

Injection-Site Rotation and Pain Minimization

Repeated injection in the same location can cause lipohypertrophy or lipoatrophy, both of which impair drug absorption. The FDA labeling recommends rotating among the three approved anatomic regions 4.

A practical rotation system: assign the left thigh to week 1, the right thigh to week 3, the left abdomen to week 5, the right abdomen to week 7, and so on. Keeping a simple log (a phone reminder with the site noted) prevents accidental reuse.

To minimize discomfort, ensure the solution is fully at room temperature. Apply a cold pack to the site for 1 to 2 minutes before swabbing with alcohol if sensitivity is high. Inject slowly. The 140 mg/mL formulation is a 1 mL volume, small enough that most patients report the injection as painless or mildly uncomfortable.

A real-world survey of 250 PCSK9 inhibitor users published in the Journal of Clinical Lipidology found that 78% rated injection discomfort as 2 or less on a 0-to-10 visual analog scale after the third self-injection 8.

What to Do if You Miss a Dose

Adherence to the PCSK9 inhibitor regimen matters for sustained LDL-C suppression. The FOURIER open-label extension (FOURIER-OLE, median follow-up 5 years) demonstrated that patients who maintained consistent dosing achieved a durable 15% relative reduction in major cardiovascular events, with no attenuation of benefit or new safety signals over prolonged exposure 9.

If a dose is missed by 7 days or fewer, administer it as soon as possible and then resume the regular schedule. If the missed dose is more than 7 days overdue, skip it entirely and administer the next dose on the originally scheduled date 4. Do not double up.

Patients who frequently miss doses should discuss barrier reduction strategies with their prescriber. Options include switching from every-2-week to once-monthly dosing (420 mg via Pushtronex), setting phone alarms, or enrolling in Amgen's patient support program for injection reminders.

Monitoring After Starting Repatha

After the first self-injection, prescribers typically order a fasting lipid panel at 4 to 8 weeks to confirm LDL-C response. A response below 25 mg/dL is common and has not been associated with adverse neurocognitive outcomes in the EBBINGHAUS substudy of FOURIER (N=1,974), which found no significant difference in cognitive function between evolocumab and placebo groups over a median of 19 months (P=0.85) 10.

Routine monitoring of hepatic transaminases or creatine kinase is not required unless the patient is on concomitant statin therapy warranting those labs. Injection-site reactions that persist beyond 48 hours or involve spreading erythema should be reported to the prescribing physician.

Patients should also be aware of rare but reported adverse effects: nasopharyngitis (4.8% vs. 4.4% placebo), upper respiratory infection (3.3% vs. 3.0%), and back pain (3.1% vs. 2.7%), all from pooled phase 3 data 6.

Traveling with Repatha

Evolocumab requires cold-chain management during travel. Use an insulated carry case with gel packs (not dry ice, which can freeze the solution). The device may pass through airport security X-ray machines without damage 4. Patients should carry a copy of their prescription or a letter from their physician to support clearance at security checkpoints.

If continuous refrigeration is unavailable, remember the 30-day room-temperature window (at or below 25°C). Mark the date on the carton when removing it from refrigeration. After 30 days at room temperature, any unused device must be discarded regardless of the printed expiration date.

For international travel, pack enough devices to cover the trip plus one extra dose in case of delays. Sharps disposal regulations vary by country; portable travel sharps containers that meet IATA standards are available at most pharmacies.

When to Contact Your Prescriber

Seek medical attention if you experience signs of a serious allergic reaction: widespread rash, facial swelling, difficulty breathing, or rapid heartbeat after injection. These events are rare. In the pooled PROFICIO phase 3 program, severe hypersensitivity was reported in <0.1% of evolocumab-treated patients 6.

Contact your prescriber if the device malfunctions mid-injection and you are unsure whether the full dose was delivered. For the SureClick autoinjector, the yellow indicator must be visible in the window. For the Pushtronex, the green completion light must be solid. If neither confirmation signal appears, do not attempt a second injection with a new device until you have spoken with your care team, as partial dose delivery may have occurred.

Patients with persistent LDL-C above target despite confirmed adherence should be evaluated for familial hypercholesterolemia genotyping and possible combination with ezetimibe or bempedoic acid per the 2022 ACC Expert Consensus Decision Pathway 11.